A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma - TrAVeRse

Study identifier:D822GC00001

ClinicalTrials.gov identifier:NCT05951959

EudraCT identifier:N/A

CTIS identifier:2023-505205-16

Recruitment Complete

Official Title

A Multicentre, Phase II, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

Medical condition

Mantle Cell Lymphoma (MCL)

Phase

Phase 2

Healthy volunteers

No

Study drug

Acalabrutinib, Venetoclax, Rituximab

Sex

All

Actual Enrollment

108

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 13 Dec 2023
Estimated Primary Completion Date: 07 Jul 2028
Estimated Study Completion Date: 07 Jul 2028

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria